ReviewWorld journal of gastroenterology2014
Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Metabolic dysfunction-associated fatty liver in type 2 diabetes mellitus patient: can a systematic review of and meta-analysis of commonly used TCM-preparation shed light on their efficacy?Frontiers in pharmacology · 2025Pooled it
- Association of circulating vaspin levels and patients with metabolic-associated fatty liver disease: a systematic review and meta-analysis.Lipids in health and disease · 2022Pooled it
- Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study.Journal of diabetes and its complications · 2023Trial
- Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial.BMC cardiovascular disorders · 2022Trial
- Metformin's disruption of gluconeogenesis in type 2 diabetes impairments of the cori and alanine cycles as hidden drivers of metabolic waste accumulation, NF-κBHIF-1α-mediated low-grade inflammation, and multisystem dysfunction.Problemy endokrinologii · 2026Review
- Diabetes and liver cirrhosis: shared pathways and clinical implications - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Association of cardiometabolic index with non-alcoholic fatty liver disease among Iranian adults of the amol cohort study.BMC gastroenterology · 2025Article
- Value of elevated 1-hour post-load plasma glucose level in identifying risk of MAFLD in non-diabetic obese children and adolescents.BMC pediatrics · 2025Article
- U-shaped association of the stress hyperglycemia ratio for all-cause and cardiovascular mortality in patients with NAFLD: results from the NHANES database prospective cohort study.BMC gastroenterology · 2025Article
- The Occurrence of Non-Alcoholic Fatty Liver Disease among Individuals with Diabetes Mellitus: A Comparative Study.Journal of pharmacy & bioallied sciences · 2025Article
- Effect of Oral Microbiota Composition on Metabolic Dysfunction-Associated Steatotic Liver Disease in the General Population.Journal of clinical medicine · 2025Article
- Association of MASLD Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors.Journal of viral hepatitis · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.Frontiers in medicine · 2025Review
- A 4-year cohort study of the effects of PNPLA3 rs738409 genotypes on liver fat and fibrosis and gut microbiota in a non-fatty liver population.Environmental health and preventive medicine · 2025Article
- Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review.Cureus · 2024Review
- Article
- Tenovin-1, a Selective SIRT1/2 Inhibitor, Attenuates High-fat Diet-induced Hepatic Fibrosis via Inhibition of HSC Activation in ZDF Rats.International journal of biological sciences · 2024Article
- Utility of Indices Obtained during Medical Checkups for Predicting Fatty Liver Disease in Non-obese People.Internal medicine (Tokyo, Japan) · 2023Observational
- Endocrinology for the hepatologist.Clinical liver disease · 2023Article
- High Prevalence of Severe Hepatic Fibrosis in Type 2 Diabetic Outpatients Screened for Non-Alcoholic Fatty Liver Disease.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with diabetes mellitus and increasing evidence suggests that patients with type 2 diabetes are at a particularly high risk for developing the progressive forms of NAFLD, non-alcoholic steatohepatitis and associated advanced liver fibrosis. Moreover, diabetes is an independent risk factor for NAFLD progression, and for hepatocellular carcinoma development and liver-related mortality in prospective studies. Notwithstanding, patients with NAFLD have an elevated prevalence of prediabetes. Recent studies have shown that NAFLD presence predicts the development of type 2 diabetes. Diabetes and NAFLD have mutual pathogenetic mechanisms and it is possible that genetic and environmental factors interact with metabolic derangements to accelerate NAFLD progression in diabetic patients. The diagnosis of the more advanced stages of NAFLD in diabetic patients shares the same challenges as in non-diabetic patients and it includes imaging and serological methods, although histopathological evaluation is still considered the gold standard diagnostic method. An effective established treatment is not yet available for patients with steatohepatitis and fibrosis and randomized clinical trials including only diabetic patients are lacking. We sought to outline the published data including epidemiology, pathogenesis, diagnosis and treatment of NAFLD in diabetic patients, in order to better understand the interplay between these two prevalent diseases and identify the gaps that still need to be fulfilled in the management of NAFLD in patients with diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.